Literature DB >> 11696002

An active immunization approach to generate protective catalytic antibodies.

J Wang1, Y Han, M F Wilkinson.   

Abstract

We report that mice immunized with a phosphate immunogen produced polyclonal catalytic antibodies (PCAbs) that catalysed the hydrolysis of carbaryl, a widely used broad-spectrum carbamate insecticide that exerts toxic effects in animals and humans. The reaction catalysed by the PCAbs (IgGs) obeyed Michaelis-Menten kinetics in vitro with the following values at pH 8.0 and 25 degrees C: K(m) approximately 8.0 microM, k(cat)=4.8x10(-3)-5.8x10(-1), k(cat)/k(non-cat)=5.6x10(1)-6.8x10(3) (where k(non-cat) is the rate constant of the reaction in the absence of added catalyst). The PCAbs were also active in whole sera under physiological conditions in vitro. The PCAbs induced in vivo were also active in vivo, as immunization with the phosphate immunogen decreased the mouse blood concentration of carbaryl. To our knowledge, this is the first report demonstrating that active immunization generates antibodies possessing therapeutic catalytic function in vivo. We propose that active immunization schemes that induce enzymically active antibodies may provide a highly specific therapeutic approach for degrading toxic substances.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11696002      PMCID: PMC1222212          DOI: 10.1042/0264-6021:3600151

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  23 in total

1.  Multiple event activation of a generic prodrug trigger by antibody catalysis.

Authors:  D Shabat; C Rader; B List; R A Lerner; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

2.  A general kinetic approach to investigation of active-site availability in macromolecular catalysts.

Authors:  M Resmini; S Gul; S Carter; S Sonkaria; C M Topham; G Gallacher; K Brocklehurst
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

3.  Subacute neurotoxicity following long-term exposure to carbaryl.

Authors:  R A Branch; E Jacqz
Journal:  Am J Med       Date:  1986-04       Impact factor: 4.965

4.  Evaluation of commercial conjugates for fluorescent antibody detection of slamonellae.

Authors:  B M Thomason; G A Hebert
Journal:  Appl Microbiol       Date:  1974-05

5.  Chemical and metabolic characteristics of 1-naphthyl-beta-D-glucoside.

Authors:  H W Dorough; J P McManus; S S Kumar; R A Cardona
Journal:  J Agric Food Chem       Date:  1974 Jul-Aug       Impact factor: 5.279

6.  Degradation of certain organophosphate and carbamate insecticides by human brain esterases.

Authors:  K Sakai; F Matsumura
Journal:  Toxicol Appl Pharmacol       Date:  1971-08       Impact factor: 4.219

7.  Antibody-catalyzed degradation of cocaine.

Authors:  D W Landry; K Zhao; G X Yang; M Glickman; T M Georgiadis
Journal:  Science       Date:  1993-03-26       Impact factor: 47.728

8.  Carcinogenic and cocarcinogenic studies with carbaryl following topical exposure in mice.

Authors:  Y Shukla; M Antony; N K Mehrotra
Journal:  Cancer Lett       Date:  1992-02-29       Impact factor: 8.679

9.  A teratogenic study of carbaryl in Swiss albino mice.

Authors:  A Mathur; P Bhatnagar
Journal:  Food Chem Toxicol       Date:  1991-09       Impact factor: 6.023

10.  A polyclonal antibody preparation with Michaelian catalytic properties.

Authors:  G Gallacher; C S Jackson; M Searcey; G T Badman; R Goel; C M Topham; G W Mellor; K Brocklehurst
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

View more
  1 in total

1.  Improvement in hydrolytic antibody activity by change in haptenic structure from phosphate to phosphonate with retention of a common leaving-group determinant: evidence for the 'flexibility' hypothesis.

Authors:  Sheraz Gul; Sanjiv Sonkaria; Surapong Pinitglang; José Florez-Alvarez; Syeed Hussain; Emrys W Thomas; Elizabeth L Ostler; Gerard Gallacher; Marina Resmini; Keith Brocklehurst
Journal:  Biochem J       Date:  2003-12-15       Impact factor: 3.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.